Holen Sie sich die Stockscreener-App
3.01
5.05%
-0.16
Handel nachbörslich:
3.02
0.01
+0.33%
Schlusskurs vom Vortag:
$3.17
Offen:
$3.18
24-Stunden-Volumen:
2.81M
Relative Volume:
1.67
Marktkapitalisierung:
$343.28M
Einnahmen:
$884.00K
Nettoeinkommen (Verlust:
$-103.64M
KGV:
-2.1586
EPS:
-1.3944
Netto-Cashflow:
$-95.45M
1W Leistung:
-17.08%
1M Leistung:
+2.03%
6M Leistung:
+5.99%
1J Leistung:
-26.76%
1-Tages-Spanne:
$2.895
$3.19
1-Wochen-Bereich:
$2.895
$3.77
52-Wochen-Spanne:
$1.955
$6.16
Perspective Therapeutics Inc Stock (CATX) Company Profile
Firmenname
Perspective Therapeutics Inc
Sektor
Branche
Telefon
509-375-1202
Adresse
350 Hills Street, Suite 106, Richland
Compare CATX vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
3.01 | 343.28M | 884.00K | -103.64M | -95.45M | -1.3944 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-10-10 | Eingeleitet | BTIG Research | Buy |
| 2025-03-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-01 | Eingeleitet | Wedbush | Outperform |
| 2024-09-25 | Eingeleitet | Truist | Buy |
| 2024-07-25 | Eingeleitet | BofA Securities | Buy |
| 2024-05-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Perspective Therapeutics Inc Aktie (CATX) Neueste Nachrichten
CATX: Key Management Meeting Insights from BTIG Analyst - GuruFocus
Perspective Therapeutics, Inc. Announces Executive Changes - marketscreener.com
Perspective Therapeutics Names Paul Lyne Chief Science Officer as Co-Founder Michael Schultz Moves to Advisory Role - marketscreener.com
Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor - The Manila Times
Perspective Therapeutics taps Merck KGaA oncology chief in planned science shift - Stock Titan
Perspective Therapeutics (CATX) 2024 Cantor Fitzgerald Global Healthcare Conference summary - Quartr
Perspective Therapeutics (CATX) Q4 2025 earnings summary - Quartr
Perspective Therapeutics (CATX) Proxy filing Summary - Quartr
Perspective Therapeutics (CATX) Morgan Stanley 22nd Annual Global Healthcare Conference summary - Quartr
Perspective Therapeutics (CATX) UBS Global Healthcare Conference Summary - Quartr
Perspective Therapeutics (CATX) Bank of America Global Healthcare Conference 2026 summary - Quartr
Perspective Therapeutics Expands Radiopharmaceutical Pipeline to Target Brain Tumors - sekbernews.id
Perspective Therapeutics (CATX) Reports Encouraging Early Data Across Multiple Radiopharmaceutical Trials - Yahoo Finance
Perspective Therapeutics Advances Next-Generation 212Pb Radiopharmaceuticals for Solid Tumor Treatment and Melanoma - Minichart
Perspective Therapeutics Highlights Progress in Alpha Radiopharmaceutical Pipeline - TipRanks
Perspective Therapeutics (CATX) updates radiopharmaceutical oncology pipeline presentation - Stock Titan
Millennium reports 4.89M shares (4.3%) in Perspective Therapeutics | CATX SEC FilingForm SCHEDULE 13G - Stock Titan
CATX: Analyst Engages with Management in Virtual Discussion - GuruFocus
Perspective Therapeutics, Inc. Actuals & Estimates (AMEX:CATX) - TradingView
Perspective Therapeutics, Inc. Actuals & Estimates (TRADEGATE:AAJ0) - TradingView
Enterprise value to revenue forward of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView
Price to earnings forward of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView
CATX Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView
Perspective Therapeutics Inc (CATX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Perspective Therapeutics Inc (CATX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Perspective Therapeutics Inc (CATX) Institutional Confidence - TradingKey
Perspective Therapeutics Inc (CATX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Perspective Therapeutics Inc (CATX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Perspective Therapeutics Inc (CATX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Perspective Therapeutics Inc (CATX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CATX Q1 2026 Earnings: Narrower-Than-Expected Loss Supports Investor ConfidenceEarnings Revision Downgrade - dars.gov.et
Perspective Therapeutics Inc - TradingKey
Perspective Therapeutics Inc (CATX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Analysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Intellia Therapeutics (NTLA) - The Globe and Mail
Enliven Therapeutics Surges on Promising Leukemia Drug Trial ResultsEarnings Outlook Update - newsline.com
Perspective Therapeutics Doses First Meningioma Patient in Phase 1/2a Study Cohort - Moomoo
CATX Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Clinical ProgressForward Guidance Trends - newsline.com
Perspective Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Radioligand Therapy Market is Expected to Grow Rapidly by 2036, Estimates DelveInsight - openPR.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Wedbush Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial - Yahoo Finance
Perspective Therapeutics (CATX) Initiates Meningioma Patient Stu - GuruFocus
Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study - The Manila Times
Targeted alpha therapy trial doses first patient for common brain tumor - Stock Titan
Perspective Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Perspective Therapeutics (CATX) Gets a Buy from Oppenheimer - The Globe and Mail
Perspective Therapeutics (CATX) Gets a Hold from Bank of America Securities - The Globe and Mail
Perspective Therapeutics Advances Next-Generation 212Pb Radiopharmaceuticals for Solid Tumor Oncology Treatment - Minichart
Perspective updates corporate presentation detailing 212Pb radiopharmaceutical pipeline and regional production strategy - TradingView
Finanzdaten der Perspective Therapeutics Inc-Aktie (CATX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Perspective Therapeutics Inc-Aktie (CATX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Williamson Robert F III | Director |
Nov 12 '25 |
Buy |
2.10 |
9,498 |
19,946 |
9,864 |
2.36%
Kapitalisierung:
|
Volumen (24h):